PXD061932-1

PXD061932 is an original dataset announced via ProteomeXchange.

Title	CSF proteomics of aducanumab treated APP-SAA triple knock-in mice
Description	Anti-amyloid β-peptide (Aβ) immunotherapy was developed as treatment for Alzheimer’s disease to reduce and prevent amyloid plaque pathology and its downstream consequences. Efficient amyloid plaque clearance has been proven in clinical trials with Aducanumab, Lecanemab and Donanemab. At least two of these antibodies slow memory decline to some extent and have beneficial effects on daily living activities. The therapeutic effects correlate with the efficacy of plaque removal. However, treatment is associated with adverse side-effects, such as oedema and haemorrhages, which are potentially linked to the induced immune response. To improve therapeutic safety, it is therefore imperative to understand the consequences of anti-Aβ antibody treatment on immune cell function. Here, we investigated the effects of long-term chronic Aducanumab treatment on amyloid plaque pathology and microglial response in the APP-SAA triple knock-in mouse model. Mice were treated weekly with Aducanumab from 4-8 months of age. Long-term treatment with Aducanumab results in a robust and dose-dependent removal of amyloid plaque pathology, with a higher efficiency for removing diffuse over dense-core plaques. Analysis of the CSF proteome indicates a reduction of markers for neurodegeneration including Tau and α-Synuclein, as well as immune cell related proteins.
HostingRepository	PRIDE
AnnounceDate	2025-08-25
AnnouncementXML	Submission_2025-08-24_17:53:50.327.xml
DigitalObjectIdentifier
ReviewLevel	Peer-reviewed dataset
DatasetOrigin	Original dataset
RepositorySupport	Unsupported dataset by repository
PrimarySubmitter	Stephan Mueller
SpeciesList	scientific name: Mus musculus (Mouse); NCBI TaxID: 10090;
ModificationList	monohydroxylated residue; acetylated residue; iodoacetamide derivatized residue
Instrument	timsTOF Pro

Revision	Datetime	Status	ChangeLog Entry
0	2025-03-17 10:31:06	ID requested
⏵ 1	2025-08-24 17:53:51	announced

10.1186/s13024-025-00878-1;

de Weerd L, Hummel S, M, ü, ller SA, Paris I, Sandmann T, Eichholtz M, Gr, ö, ger R, Englert AL, Wagner S, Ha C, Davis SS, Warkins V, Xia D, Nuscher B, Berghofer A, Reich M, Feiten AF, Schlepckow K, Willem M, Lichtenthaler SF, Lewcock JW, Monroe KM, Brendel M, Haass C, immunotherapy attenuates microglial activation without inducing exhaustion at residual plaques. Mol Neurodegener, 20(1):92(2025) [pubmed]

submitter keyword: cerebrospinal fluid, mouse, diaPASEF,aducanumab

Dr Stefan
contact affiliation	DZNE Munich, Neuroproteomics, Feodor-Lynen-Str. 17, 81377 München, Germany
contact email	stefan.lichtenthaler@dzne.de
lab head
Stephan Mueller
contact affiliation	DZNE Munich Neuroproteomics
contact email	stephan.mueller@dzne.de
dataset submitter

Dataset FTP location NOTE: Most web browsers have now discontinued native support for FTP access within the browser window. But you can usually install another FTP app (we recommend FileZilla) and configure your browser to launch the external application when you click on this FTP link. Or otherwise, launch an app that supports FTP (like FileZilla) and use this address: ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2025/08/PXD061932

PRIDE project URI

• PRIDE
  1. PXD061932
     1. Label: PRIDE project
     2. Name: CSF proteomics of aducanumab treated APP-SAA triple knock-in mice